May 4, 2022 10:49 AM EDT

BerGenBio narrows R&D to focus on NSCLC and Covid-19; Oral SERDs see another setback as G1 drops program

Kyle LaHucik

Senior Reporter

Max Gelman

Senior Editor

BerGenBio said it will prioritize its pipeline to focus on first-line non-small cell lung cancer and Covid-19 with its lead drug bemcentinib. That means work …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BerGenBio narrows R&D to focus on NSCLC and Covid-19; Oral SERDs see another setback as G1 drops program

Kyle LaHucik

Senior Reporter

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

BerGen­Bio nar­rows R&D to fo­cus on NSCLC and Covid-19; Oral SERDs see an­oth­er set­back as G1 drops pro­gram

Senior Reporter

Senior Editor

Sign up to read this article for free.

BerGenBio narrows R&D to focus on NSCLC and Covid-19; Oral SERDs see another setback as G1 drops program